iohexol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 1461 66108-95-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iohexol
An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
  • Molecular weight: 821.14
  • Formula: C19H26I3N3O9
  • CLOGP: -2.44
  • LIPINSKI: 3
  • HAC: 12
  • HDO: 8
  • TPSA: 199.89
  • ALOGS: -3.01
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 95 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4597.21 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.80 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 1985 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 890.30 31.92 401 6187 165401 63317033
Sneezing 567.36 31.92 163 6425 18055 63464379
Pruritus 454.11 31.92 340 6248 361113 63121321
Contrast media reaction 442.99 31.92 80 6508 1045 63481389
Erythema 311.93 31.92 205 6383 175546 63306888
Extravasation 286.88 31.92 63 6525 2309 63480125
Throat irritation 232.13 31.92 101 6487 37546 63444888
Contrast media allergy 231.54 31.92 53 6535 2348 63480086
Throat tightness 177.27 31.92 74 6514 24813 63457621
Dyspnoea 140.44 31.92 247 6341 661066 62821368
Anaphylactic reaction 121.32 31.92 79 6509 66021 63416413
Anaphylactic shock 106.41 31.92 51 6537 23582 63458852
Chest discomfort 87.57 31.92 80 6508 109889 63372545
Chills 66.86 31.92 70 6518 113308 63369126
Eye swelling 65.54 31.92 37 6551 23881 63458553
Drug ineffective 62.45 31.92 16 6572 1044749 62437685
Pharyngeal oedema 59.89 31.92 29 6559 13692 63468742
Cough 57.29 31.92 106 6482 292637 63189797
Laryngeal oedema 54.52 31.92 21 6567 5697 63476737
Local anaesthetic systemic toxicity 51.29 31.92 13 6575 886 63481548
Hypersensitivity 51.12 31.92 101 6487 292584 63189850
Aneurysm ruptured 47.06 31.92 11 6577 533 63481901
Drug reaction with eosinophilia and systemic symptoms 46.78 31.92 34 6554 33802 63448632
Paraesthesia oral 45.34 31.92 27 6561 19229 63463205
Fatigue 45.17 31.92 18 6570 888010 62594424
Eye pruritus 43.50 31.92 26 6562 18645 63463789
Patent ductus arteriosus 41.92 31.92 16 6572 4234 63478200
Contrast encephalopathy 39.51 31.92 7 6581 81 63482353
Swelling face 38.83 31.92 40 6548 63435 63418999
Blood pressure decreased 38.02 31.92 40 6548 64982 63417452
Nasal congestion 37.70 31.92 40 6548 65620 63416814
Tongue pruritus 36.81 31.92 9 6579 529 63481905
Anaphylactoid reaction 36.66 31.92 14 6574 3709 63478725
Dysphagia 35.76 31.92 45 6543 88540 63393894
No adverse event 34.61 31.92 31 6557 41374 63441060
Papule 34.13 31.92 15 6573 5676 63476758
Sensation of foreign body 33.37 31.92 14 6574 4731 63477703
Swollen tongue 33.01 31.92 28 6560 34772 63447662
Tachypnoea 32.47 31.92 21 6567 17281 63465153
Tremor 32.46 31.92 53 6535 132186 63350248

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 584.83 28.14 245 4681 62132 34889873
Sneezing 402.43 28.14 102 4824 5140 34946865
Contrast media reaction 325.51 28.14 63 4863 883 34951122
Pruritus 260.66 28.14 190 4736 141791 34810214
Erythema 224.59 28.14 145 4781 88635 34863370
Contrast media allergy 196.86 28.14 37 4889 438 34951567
Extravasation 196.63 28.14 47 4879 1843 34950162
Anaphylactic reaction 160.24 28.14 82 4844 32219 34919786
Rash maculo-papular 106.67 28.14 60 4866 28391 34923614
Anaphylactic shock 95.33 28.14 46 4880 15895 34936110
Throat tightness 81.62 28.14 34 4892 8324 34943681
Chills 74.23 28.14 73 4853 80970 34871035
Throat irritation 67.70 28.14 32 4894 10553 34941452
Acute kidney injury 61.06 28.14 133 4793 304855 34647150
Overlap syndrome 47.75 28.14 9 4917 108 34951897
Anaphylactoid shock 47.41 28.14 11 4915 377 34951628
Hypersensitivity 45.03 28.14 49 4877 60986 34891019
Drug reaction with eosinophilia and systemic symptoms 44.48 28.14 37 4889 32975 34919030
Vomiting 43.86 28.14 103 4823 247518 34704487
Eye pruritus 39.93 28.14 20 4906 7469 34944536
Dyspnoea 35.66 28.14 125 4801 376657 34575348
Rash 34.43 28.14 88 4838 222664 34729341
Blood pressure decreased 33.93 28.14 39 4887 51476 34900529
Death 32.75 28.14 8 4918 398041 34553964
Eye swelling 31.88 28.14 19 4907 9976 34942029
Drug ineffective 30.84 28.14 13 4913 456738 34495267
Nephropathy toxic 30.26 28.14 20 4906 12568 34939437
Hypotension 28.65 28.14 82 4844 221567 34730438

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 1216.54 26.77 566 10635 184635 79548552
Sneezing 863.57 26.77 246 10955 19437 79713750
Contrast media reaction 688.93 26.77 134 11067 1936 79731251
Pruritus 641.84 26.77 490 10711 394158 79339029
Erythema 458.38 26.77 320 10881 222970 79510217
Extravasation 441.40 26.77 103 11098 3647 79729540
Contrast media allergy 359.66 26.77 81 11120 2441 79730746
Throat irritation 266.25 26.77 125 11076 40821 79692366
Anaphylactic reaction 247.04 26.77 151 11050 83592 79649595
Throat tightness 218.55 26.77 97 11104 27810 79705377
Anaphylactic shock 186.15 26.77 94 11107 35902 79697285
Dyspnoea 155.13 26.77 358 10843 856667 78876520
Chills 133.54 26.77 137 11064 160097 79573090
Rash maculo-papular 113.56 26.77 80 11121 55998 79677189
Eye swelling 97.02 26.77 55 11146 26413 79706774
Chest discomfort 92.09 26.77 105 11096 137939 79595248
Drug reaction with eosinophilia and systemic symptoms 84.66 26.77 71 11130 64173 79669014
Hypersensitivity 81.57 26.77 138 11063 262101 79471086
Eye pruritus 78.79 26.77 44 11157 20526 79712661
Drug ineffective 77.18 26.77 28 11173 1080885 78652302
Pharyngeal oedema 65.59 26.77 36 11165 16236 79716951
Acute kidney injury 65.44 26.77 190 11011 519214 79213973
Rash 64.82 26.77 203 10998 578155 79155032
Anaphylactoid shock 63.84 26.77 16 11185 765 79732422
Blood pressure decreased 63.50 26.77 74 11127 99392 79633795
Cough 62.26 26.77 150 11051 366639 79366548
Vomiting 60.71 26.77 218 10983 665610 79067577
Aneurysm ruptured 60.67 26.77 16 11185 938 79732249
Laryngeal oedema 56.43 26.77 26 11175 8103 79725084
Nephropathy toxic 55.47 26.77 35 11166 20384 79712803
Hypotension 52.46 26.77 158 11043 440159 79293028
No adverse event 50.83 26.77 42 11159 37150 79696037
Off label use 48.90 26.77 34 11167 907181 78826006
Angioedema 47.56 26.77 56 11145 75979 79657208
Papule 46.19 26.77 22 11179 7385 79725802
Nasal congestion 45.61 26.77 55 11146 76497 79656690
Swelling face 45.46 26.77 53 11148 71159 79662028
Lip swelling 45.37 26.77 41 11160 40870 79692317
Eyelid oedema 43.67 26.77 26 11175 13661 79719526
Tongue pruritus 43.24 26.77 11 11190 559 79732628
Tachypnoea 41.31 26.77 35 11166 32028 79701159
Rash erythematous 40.26 26.77 45 11156 57724 79675463
Fatigue 40.17 26.77 43 11158 929684 78803503
Infusion site extravasation 39.73 26.77 22 11179 10086 79723101
Anaphylactoid reaction 39.70 26.77 18 11183 5404 79727783
Paraesthesia oral 38.63 26.77 28 11173 20443 79712744
Contrast encephalopathy 37.74 26.77 8 11193 180 79733007
Diarrhoea 37.72 26.77 41 11160 880448 78852739
Death 36.51 26.77 17 11184 566497 79166690
Sensation of foreign body 36.27 26.77 17 11184 5505 79727682
Loss of consciousness 35.46 26.77 75 11126 167868 79565319
Lacrimation increased 34.13 26.77 27 11174 22450 79710737
Ocular hyperaemia 32.72 26.77 29 11172 28177 79705010
Injection site extravasation 32.50 26.77 19 11182 9650 79723537
Weight decreased 31.27 26.77 6 11195 355192 79377995
Swollen tongue 31.11 26.77 34 11167 42536 79690651
Tachycardia 30.39 26.77 73 11128 177695 79555492
Toxic skin eruption 30.09 26.77 25 11176 22268 79710919
Dysphagia 29.88 26.77 58 11143 122078 79611109
Cyanosis 29.42 26.77 26 11175 25156 79708031
Shock 28.77 26.77 33 11168 43515 79689672
Arthralgia 28.70 26.77 23 11178 571780 79161407
Overlap syndrome 28.37 26.77 9 11192 1015 79732172
Flushing 28.08 26.77 47 11154 88221 79644966
Fall 27.92 26.77 17 11184 487612 79245575
Cold sweat 27.40 26.77 22 11179 18677 79714510
Rash pustular 27.29 26.77 18 11183 11293 79721894

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08AB02 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA N0000010258 X-Ray Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000180185 Radiographic Contrast Agent
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:37338 contrast media
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

None




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.73 acidic
pKa2 11.33 acidic
pKa3 12.2 acidic
pKa4 13.65 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018251 VUID
N0000146581 NUI
D01817 KEGG_DRUG
4018251 VANDF
C0022005 UMLSCUI
CHEBI:31709 CHEBI
CHEMBL1200455 ChEMBL_ID
D007472 MESH_DESCRIPTOR_UI
DB01362 DRUGBANK_ID
4848 INN_ID
4419T9MX03 UNII
3730 PUBCHEM_CID
5956 RXNORM
4904 MMSL
d01456 MMSL
000673 NDDF
109218004 SNOMEDCT_US
395751002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1401 INJECTION, SOLUTION 140 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1401 INJECTION, SOLUTION 140 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1401 INJECTION, SOLUTION 140 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1411 INJECTION, SOLUTION 180 mg ORAL NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1411 INJECTION, SOLUTION 180 mg ORAL NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1411 INJECTION, SOLUTION 180 mg ORAL NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections